Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Osteosarcoma in rats receiving long-term PTH injection].

Ryo Okazaki1

  • 1Third Department of Medicine, Teikyo University School of Medicine.

Clinical Calcium
|March 19, 2005
PubMed
Summary

Human parathyroid hormone (PTH) effectively treats osteoporosis by increasing bone density and reducing fractures. Concerns about osteosarcoma in rats are unlikely to apply to human patients due to significant biological differences.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A noninvasive urinary microRNA-based assay for the detection of pancreatic cancer from early to late stages: a case control study.

EClinicalMedicine·2025
Same author

Studies on the inhibition of methanogenesis and dechlorination by (4-hydroxyphenyl) chloromethanesulfonate.

Journal of pesticide science·2022
Same author

Laparoscopic approach as a safe and effective option for incarcerated femoral hernias.

Asian journal of endoscopic surgery·2021
Same author

Clinical performance of a novel chemiluminescent enzyme immunoassay for FGF23.

Journal of bone and mineral metabolism·2021
Same author

[Body weight and bone/calcium metabolism. Obesity and vitamin D.]

Clinical calcium·2018
Same author

Factors associated with inadequate responses to risedronate in Japanese patients with osteoporosis.

Journal of bone and mineral metabolism·2018

Area of Science:

  • Endocrinology
  • Oncology
  • Bone Biology

Context:

  • Human parathyroid hormone (1-34) demonstrates efficacy in increasing bone mineral density and reducing fracture risk in osteoporotic patients.
  • Long-term administration of hPTH (1-34) in rats showed a high incidence of osteosarcoma, raising safety concerns.
  • Differences in bone metabolism and dosage/duration of treatment between rats and humans are critical factors in risk assessment.

Purpose:

  • To evaluate the safety and efficacy of human parathyroid hormone (1-34) for osteoporosis treatment.
  • To address concerns regarding osteosarcoma risk associated with hPTH (1-34) therapy.
  • To reconcile findings from rodent studies with potential human therapeutic applications.

Summary:

  • Daily injections of human PTH (1-34) improve bone mineral density and decrease fracture incidence in osteoporotic individuals within 18 months.
  • While a 2-year study in rats showed a high rate of osteosarcoma (53%) with hPTH (1-34), experts largely agree this does not translate to human risk.
  • Key differentiating factors include species-specific bone metabolism, significantly higher dosages used in rats (12-25x human dose), and prolonged exposure duration in rodents (80-90% lifespan) versus humans (2-3% lifespan).

Impact:

  • The findings support the continued investigation and potential clinical use of hPTH (1-34) for osteoporosis, despite initial safety signals from animal models.
  • Highlights the importance of species-specific data interpretation in preclinical safety assessments for drug development.
  • Provides a scientific basis for understanding the differential risk of osteosarcoma between rats and humans when treated with parathyroid hormone.

Related Experiment Videos